The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Achillion Pharmaceuticals Inc. (“Achilion” or “Company”) (NASDAQ GS:ACHN) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding Company’s experimental hepatitis C drug.
Specifically, on September 30, 2013, the Company disclosed it received a response from the U.S. Food and Drug Administration on the clinical hold already in effect since June 2013, related to sovaprevir, Achillion's NS3 protease inhibitor.
The FDA response indicated that, “while Achillion's submission addressed all issues noted in the FDA's June 29, 2013 letter, the FDA concluded that the removal of the clinical hold is not warranted.” Presumably, the FDA’s decision to continue the hold was because it observed high levels of liver enzymes in healthy patients, which can indicate damage, when sovaprevir was combined with two medicines used to treat HIV infection.
On this news, shares of Achillion shares fell $4.30 per share, more than 59.53% on intraday trading, to a price of $2.94 on September 30, 2013.Even though the sovaprevir trial was on hold since June, as recently as September 10, 2013, the Company’s President/CEO Milind S. Deshpande stated at the Robert W. Baird and Co. Health Care Conference that he anticipated the Company would “receive a favorable response from the [FDA].” Moreover, he said with a 99.99% confidence interval that there is no overlap between the exposures we see in our – [sic] with our clinical doses versus the exposure we’re seeing in the DDI study.” Wolf Haldenstein has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in United States federal and state courts. Please visit the Wolf Haldenstein website ( http://www.whafh.com) for more information about the firm. Please contact us if you own Achillion common stock and wish to discuss this matter with us, or have any questions concerning your rights and interests:
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV